Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge

Hooper, Jay W.; Golden, Joseph W.; Ferro, Anthony M.; King, Alan D.

doi:10.1016/j.vaccine.2006.11.017

Cited by 162 publications

(114 citation statements)

References 36 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…The protective efficacy of genetic immunization was demonstrated previously both in mice and nonhuman primates (Hooper et al, 2003;Hooper et al, 2007). However, in the present study, 4DNAmix of G3 and 4FPmix of G5 elicited antibodies against A33 and B5, although they did not protect the mice.…”

contrasting

confidence: 59%

Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity

et al. 2016

View full text Add to dashboard Cite

Please cite this article as: Bissa, M., Quaglino, E., Zanotto, C., Illiano, E., Rolih, V., Pacchioni, S., Cavallo, F., De Giuli Morghen, C., Radaelli, A., Protection of mice against the highly pathogenic VV IHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity, Antiviral Research (2016Research ( ), doi: 10.1016Research ( / j.antiviral.2016 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. and fowlpox (FP) recombinants that expressed the VV L1R, A27L, A33R, and B5R genes were generated (4DNAmix, 4FPmix, respectively) and tested in mice using novel administration routes. Mice were primed with 4DNAmix by electroporation, and boosted with 4FPmix applied intranasally. The lethal VV IHD-J strain was then administered by intranasal challenge. All of the mice receiving 4DNAmix followed by 4FPmix, and 20% of the mice immunized only with 4FPmix, were protected. The induction of specific humoral and cellular immune responses directly correlated with this protection. In particular, higher anti-A27antibodies and IFNγ-producing T lymphocytes were measured in the blood and spleen of the protected mice, as compared to controls. VV IHD-J neutralizing antibodies in sera from the protected mice suggest that the prime/ boost vaccination regimen with 4DNAmix plus 4FPmix may be an effective and safe mode to induce protection against smallpox and poxvirus zoonotic infections. The electroporation/ intranasal administration routes contributed to effective immune responses and mouse survival.

show abstract

contrasting

confidence: 59%

Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Currently, targets of orthopoxvirus subunits vaccines include D8, H3, A33, A27, L1 and B5 [16][17][18][19][20][21][22][23][24]. We developed a combination DNA vaccine (termed 4pox) that targets four orthopoxvirus antigens (L1, A27, B5 and A33) [21][22][23]. Orthopoxviruses have two antigenically distinct infectious forms, extracellular enveloped virions (EEV) and intracellular mature virions (IMV) [25].…”

Section: Subject Termsmentioning

confidence: 99%

“…Accordingly, our 4pox vaccine targets multiple proteins on both infectious forms of orthopoxviruses, the IMV (L1 and A27) and the EEV (B5 and A33). Plasmids expressing these genes elicit antibody responses against each protein when delivered to the skin by gene-gun or electroporation [20][21][22][23]. Importantly, the 4pox vaccine can protect mice and non-human primates from lethal challenge with VACV or monkeypox virus, respectively [21][22][23].…”

Section: Subject Termsmentioning

confidence: 99%

Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies

Golden

Josleyn

Hooper

2008

Vaccine

Self Cite

View full text Add to dashboard Cite

“…Studies with DNA vaccinations in animal models have shown promising results in infectious diseases such as hepatitis B, [24][25][26][27] HIV, 28 malaria 29 and smallpox. 30 Vaccination studies using intradermal electroporation in mice with DNA coding for prostate-specific antigen (PSA) gave increased level of PSA-specific T cells 31,32 and a Phase I/II clinical trial (NCT00859729) is currently running.…”

Section: Introductionmentioning

confidence: 99%

Duration and level of transgene expression after gene electrotransfer to skin in mice

et al. 2010

View full text Add to dashboard Cite

Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge

Cited by 162 publications

References 36 publications

Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity

Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity

Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies

Duration and level of transgene expression after gene electrotransfer to skin in mice

Contact Info

Product

Resources

About